Jasper Therapeutics (NASDAQ:JSPR) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note published on Tuesday, Benzinga reports. They currently have a $70.00 price objective on the stock.

Several other equities research analysts have also issued reports on JSPR. Cantor Fitzgerald reaffirmed an overweight rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada cut their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating for the company in a research report on Wednesday, August 14th. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They set a buy rating and a $86.00 target price for the company. BTIG Research started coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They set a buy rating and a $90.00 target price for the company. Finally, Evercore ISI reissued an outperform rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of Buy and a consensus target price of $74.86.

Jasper Therapeutics Trading Up 10.3 %

JSPR stock opened at $18.28 on Tuesday. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01. The company has a fifty day simple moving average of $18.97 and a 200 day simple moving average of $21.59. The firm has a market cap of $275.37 million, a PE ratio of -3.25 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.12. As a group, analysts forecast that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JSPR. StemPoint Capital LP acquired a new position in shares of Jasper Therapeutics during the first quarter valued at about $3,794,000. Ikarian Capital LLC bought a new stake in Jasper Therapeutics in the first quarter valued at about $3,088,000. Russell Investments Group Ltd. bought a new stake in Jasper Therapeutics in the first quarter valued at about $2,343,000. Bank of New York Mellon Corp bought a new stake in Jasper Therapeutics in the second quarter valued at about $740,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Jasper Therapeutics in the first quarter valued at about $599,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.